Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Ontology highlight
ABSTRACT: The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator’s choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator’s choice (trifluridine and tipiracil, or regorafenib).
DISEASE(S): Colorectal Cancer (crc),Sarcoma,Colorectal Neoplasms
PROVIDER: 2401536 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA